Gordon Warner, MD
Sleep Medicine · Cullman, ALNPI 1194754788
Payments from drug & device makers
Across 1,225 payments — averaging $639.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$598K
- Sanofi$38K
- Mylan Specialty L.p.$35K
- GSK$31K
- Sanofi US Services Inc.$30K
- Alkermes, Inc.$18K
- plus $33K from 43 others
What the payments were for
- Consulting fees$4,1194%
- Speaking & faculty fees$65,08265%
- Travel & lodging$8,0668%
- Food & beverage$22,26422%
- Education$7961%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yupelri$33,605
- TRELEGY ELLIPTA$23,522
- Prolastin-C Liquid$10,260
- ANORO$3,600
- SYMBICORT$2,700
- Prolastin-C$1,800
- Inspire$1,596
- FISHER & PAYKEL HEALTHCARE$953
- DUPIXENT$368
- XYWAV$123
How this compares
$783,901 in reported general payments places this provider in the 90th percentile of 28 sleep medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 18 | $357,115 |
| GlassiaAlpha-1-Proteinase Inhibitor | 28 | $352,565 |
| WakixPitolisant Hcl | 16 | $231,378 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 200 | $152,674 |
| NucalaMepolizumab | 26 | $87,942 |
| Breo ElliptaFluticasone/Vilanterol | 70 | $30,165 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 28 | $20,914 |
| SunosiSolriamfetol Hcl | 24 | $20,867 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 30 | $19,519 |
| Spiriva RespimatTiotropium Bromide | 33 | $17,033 |
| Modafinil | 189 | $14,308 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 28 | $14,009 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 197 | $11,852 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 352 | $11,004 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 16 | $7,880 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $1,070 | $352,56528 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta | $30,883 | $291,695324 claims |
| Harmony Biosciences LLCWakix | $1,301 | $231,37816 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $1,712 | $38,92177 claims |
| AstraZenecaBreztri Aerosphere, Daliresp, Symbicort | $4,284 | $29,87761 claims |
| Axsome Therapeutics, Inc.Sunosi | $760 | $20,86724 claims |
| MerckBelsomra | $188 | $7,03513 claims |
| Eisai Inc.Dayvigo | $45 | $3,94812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 28 sleep medicine providers in Alabama.
Other sleep medicine in Cullman
- Bahador TafazoliCullman$26K
- Michael LedetDaphne$3M
- James RoyHuntsville$823K
- Alan ThomasBirmingham$364K
- Robert DoekelBirmingham$351K
- William AdamsBirmingham$181K
- Fred McLeodAlexander City$93K
- James GeyerTuscaloosa$61K
- Ashwin AnanthFoley$57K
- Christopher HopeOpelika$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.